Keluping® is the commercial brand name of Tunlametinib, a novel orally available MEK inhibitor independently developed in China. It selectively inhibits MEK1/2 kinase activity, blocks the MAPK signaling pathway, and suppresses the proliferation of tumor cells with relevant gene mutations.
Main Indications
For the treatment of adult patients with unresectable or metastatic solid tumors harboring NRAS mutations who have failed prior systemic therapy.
Clinical Research
A pivotal phase II clinical study showed that tunlametinib achieved promising objective response rate and durable tumor control in patients with NRAS-mutated advanced solid tumors. The safety profile was manageable, supporting its conditional marketing approval in China.
Common Side Effects
Common adverse reactions include rash, paronychia, diarrhea, edema, fatigue, increased creatine kinase, elevated liver enzymes and visual impairment.
Approval Status in China
Keluping® (Tunlametinib Capsules) was officially approved for marketing in China in 2023, with the specification of 3mg. It is a domestically innovative prescription anti-tumor drug.
Buy Keluping (Tunlametinib Capsules) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
